RT Journal Article
SR Electronic
T1 A variational model for computing the effective reproduction number of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.01.20165142
DO 10.1101/2020.08.01.20165142
A1 Alvarez, Luis
A1 Colom, Miguel
A1 Morel, Jean-Michel
YR 2020
UL http://medrxiv.org/content/early/2020/12/31/2020.08.01.20165142.abstract
AB We propose a variational model for computing the temporal effective reproduction number, R(t), of SARS-CoV-2 from the daily count of incident cases and the serial interval. The R(t) estimate is made through the minimization of a functional that enforces: (i) the ability to reproduce the incidence curve from R(t) through a renewal equation, (ii) the regularity of R(t) and (iii) the adjustment of the initial value to an initial estimate of R0 obtained from the initial exponential growth of the epidemic. The model does not assume any statistical distribution for R(t) and does not require truncating the serial interval when its distribution contains negative days. A comparative study of the solution is carried out with the standard EpiEstim method. For a particular choice of the parameters of the variational model, a good agreement is found between the estimate provided by the variational model and an estimate obtained by EpiEstim shiftef backward more than 8 days. This backward shift suggests that our model finds values for R(t) that are more than 8 days closer to present. We also examine how to extrapolate R(t) and the form of the incidence curve i(t) in the short term. An implementation and comparison of both methods, applied every day on each country, is available at www.ipol.im/ern.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research has been partially supported by Kayrros,inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval necessary; only public and anonymous data were usedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe use the COVID-19 registered daily infected from the European Centre for Disease Prevention and Control service https://www.ecdc.europa.eu/en EpiEstimSoftware to compute the effective reproduction number proposed by Cori et al. in the paper: A new framework and software to estimate time-varying reproduction numbers during epidemics published in the American Journal of Epidemiology.R(t)Effective Reproduction Number. To differentiate between the continuous and discrete cases, we use the notation R(t) in the continuous case and Rt in the discrete case.i(t)incidence curve, the number of daily tested positive registered. To differentiate between the continuous and discrete cases, we use the notation i(t) in the continuous case and it in the discrete case.Φserial interval.